Bay Bridge, San Francisco, CA
Since founding Nano Precision Medical, Dr. Mendelsohn has served as its Chief Executive Officer and sets the strategic vision for the company.
Dr. Mendelsohn received his Ph.D. in bioengineering at the UC San Francisco/UC Berkeley Joint Graduate Group in Bioengineering, Class of 2011, during which he was awarded an NSF fellowship to perform research at Kyoto University, and published multiple peer-reviewed articles describing new treatment options for Type 1 diabetes through the immuno-isolated transplantation of insulin-producing cells under the direction of Professor Tejal A. Desai. While in graduate school, Dr. Mendelsohn served as the director for the Venture Innovation Program in Life Sciences, and completed his certificate in Management of Technology with the Haas School of Business.
Dr. Mendelsohn has served as a Technical Advisor to the Alfred E. Mann Institute for Biomedical Engineering at USC, a fellow of the Startup Leadership Program, the President of UCSF’s Graduate Division Alumni Association, and is currently a board member of the Maestro Foundation.
Dr. Porter has over 20 years of experience in developing medicines for metabolic diseases with a focus on bringing innovative therapies to patients with high unmet need. Before joining NPM she served as CMO, Metabolic Diseases for Eiger Biopharmaceuticals where she led clinical development for the orphan diseases postbariatric hypoglycemia and Hutchinson-Gilford Progeria Syndrome resulting in FDA breakthrough therapy designation for both programs. She has previously served as CMO for Dance BioPharma (now Aerami Therapeutics) and Vice President, Medical Development for Amylin Pharmaceuticals where she led the R&D efforts for the Amylin-Lilly Alliance culminating in the approval of the GLP-1 agonist Bydureon, the 1st once weekly treatment for Type 2 diabetes. Prior to joining Amylin, Dr. Porter held progressively increasing leadership positions at GlaxoSmithKline Pharmaceuticals with responsibilities for the clinical strategy for Avandia and early obesity compounds and Associate Medical Director for Zeneca Pharmaceuticals.
Dr. Porter earned a BS in Biology from the College of William & Mary, an MD from Duke University and completed fellowship training in Endocrinology and Hypertension at Brigham and Women’s Hospital.
Mr. Le brings over 35 years of manufacturing, quality, and overall operations experience with devices and complex drug-device combination products. From 2011 to March 2020, Mr. Le was the Chief Technical Operations Officer for Dance Biopharm - a leader in aqueous respiratory therapy delivery with Drug and Device combination products - he built the Operations, Quality Systems, Manufacturing, Supply Chain, Product Development, Formulation, and IT. From 2009 to 2011, Mr. Le was the Chief Operating Officer for Avid Bio services, Inc., a leading contract manufacturing organization that specializes in clinical trials and commercial distribution of monoclonal antibodies and recombinant proteins. From 2007 to 2009, Mr. Le served as the EVP Manufacturing and Quality for PrimaBiomed, a cell therapy company, and as a consultant for several drug/device companies. From 2001 to 2007, Mr. Le was Senior Vice President of Operations, Product Development, Quality, and Regulatory Affairs for Nektar Therapeutics, a biopharmaceutical company, where he led the commercial formulation and device manufacturing for Exubera. From 1999 to 2001, he consulted for multiple large pharmaceutical and medical device companies (Abbott, Medtronic, Baxter, Dow Chemical) specializing in Due-diligence, Operation Effectiveness, and PAI readiness. From 1981 to 1999, Mr. Le was employed for a division of Johnson & Johnson, as the Worldwide Vice-President of Regulatory Compliance and Quality Systems. His work at Johnson & Johnson included 10+ years in operations, regulatory affairs, product development, manufacturing, and quality for ophthalmic products such as cataract devices and implants and drug products for ophthalmic surgery procedures.
Mr. Le has a B.S. in mechanical engineering, M.B.A. in Management, and completed numerous executive leadership training programs, including World Class Manufacturing at Duke University, Executive Management at Harvard University, and a QSR trainer at AAMI/FDA.
Don is a science-based business leader with over 35 years of experience in the biopharmaceutical industry and a broad background in leadership across a wide range of technologies and disease areas. Don has held director level positions in quality assurance/control and regulatory affairs (Rhone-Poulenc Rorer and Cephalon); and drug development, sales, commercial and business development (AstraZeneca). He also served as AstraZeneca's observer on the Board of Directors for PhaseBio (2014-2018) and Nano Precision Medical (2015-2019). At AstraZeneca (AZ), he was Executive Director Business Development and Early Asset (pre-Phase 3) Commercial lead for Cardiovascular, Renal and Metabolic Disease where he co-led the $2.7B acquisition of LOKELMA (hyperkalemia) from ZS Pharma and the $1.2B licensing and co-commercialization deal for TC-5214 (major depressive disorder) with Targacept. On the divestment side, Don was also co-lead on multiple projects including the ZOLADEX implant (cancer), Earlier in his career, he was the US commercial head for key brands including TOPROL-XL (heart failure, hypertension, angina); ATACAND (hypertension); ONGLYZA (diabetes); FARXIGA (diabetes); SEROQUEL (bipolar disorder) and ABRAXANE (cancer).
Mr. Dwyer is a graduate of the University of Central Connecticut (chemistry/biology) and Temple University Fox School of Business (M.B.A.).
Mr. Stedman brings 25 years of manufacturing experience with complex drug-device combination products including roles in manufacturing engineering, Six-Sigma, supply chain, program management, and outsourced contract manufacturing. Ben has served in roles of increasing responsibility over the course of his career, most recently as the Vice President of Manufacturing at Aerami Therapeutics / Dance Biopharm which is developing a nebulizing inhaler platform that included an insulin and a GLP-1 formulation. Earlier in his career, Ben was an Executive Director at Coherus Biosciences where he was responsible for clinical and commercial supply chain as the company prepared to launch the first biosimilar to Neulasta, an Associate Director at Nektar Therapeutics for several years leading up to and after the approval of Exubera, and as a Senior Manager of MAP Pharmaceuticals through Allergan’s $1B acquisition of the company. Ben began his career in semiconductor manufacturing and has experiences that translate to the NanoPortal production.
He received his B.S. degree in Manufacturing Engineering from Cal Poly, San Luis Obispo and his M.B.A. from San Jose State University. Ben is also a Six-Sigma Black Belt.
Mr. Gipson brings over 20 years of industry experience in medical devices, pharmaceuticals, and combination products, including leadership roles in operations, manufacturing, engineering, logistics, and quality. He has developed several successful teams and participated in the development and market introduction of numerous products. Antwan has served in similar roles with both publicly traded companies and venture-backed start-ups such as Allergan, Tautona Group, Cohesion Technologies (acquired by Angiotech Pharm.), and Fuisz Technologies (acquired by Biovail Corp.).
Antwan earned his B.Sc. in Engineering from Northern Michigan University, prior to serving in the United States Navy honorably, and has an M.B.A. (emphasis applied research) from Angelo State University-Texas; including post graduate work and professional certificates in Quality Engineering, Product Lifecycle Management, and Lean Manufacturing.
Dr. Roorda has more than 35 years of academic and industry experience with controlled drug delivery, medical devices, drug-device combinations, and drug- and protein-formulation. In his Ph.D. studies, he developed and characterized a hydrogel-based drug delivery technology from polymer synthesis to testing in human volunteers. At Alza Corporation, he developed a number of formulations for implantable drug delivery systems intended for low molecular weight drugs as well as macromolecules.
As a research scientist at Guidant Corporation, Dr. Roorda pioneered some of the earliest studies on the Xience V drug eluting stent program, and after the acquisition by Abbott Labs, he assumed responsibility for new product concept generation and additional IP portfolio development as a director of R&D for the endovascular division. For his work on the Xience V stent, he was awarded the Volwiler Outstanding Research Team award, the highest scientific team award at Abbott Laboratories.
Dr. Roorda has a Ph.D. from the University of Leiden, The Netherlands, and he is a registered Patent Agent. He is an inventor on 84 US patents.